Premier Alternatives

ThinkCyte

Tokyo, Japan · Founded 2016 · Privately Held (backing)

Developer of an image-based cell sorting technology designed to advance single-cell analysis for research, diagnostics, and therapeutics. ThinkCyte is based in Tokyo, Japan and was founded in 2016. Its last reported valuation was $106 million in Nov 2025. It has raised $84.7 million.

Last reported valuation
$106.4M
Oct 2026
Priced at
—
Total raised
$84.7M
Last round
—

ThinkCyte key facts

as of Oct 2026
  • Developer of an image-based cell sorting technology designed to advance single-cell analysis for research, diagnostics, and therapeutics.
  • ThinkCyte is valued at approximately $106.4M as of Oct 2026 (last reported valuation).
  • It has raised $84.7M; the latest was Later Stage VC ($3.9M) in Nov 2025.
  • Notable investors include Google for Startups, Global Brain, SMBC Venture Capital, J-Startup, Berkeley SkyDeck — 27 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$106.4M

ThinkCyte's last reported valuation, Nov 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Private Market View
More of ThinkCyte with a free Private Market View account
  • ·The complete investor list: 27 names
  • ·Watch ThinkCyte: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

ThinkCyte funding rounds

No rounds on record

No funding rounds for ThinkCyte are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

ThinkCyte valuation

ThinkCyte's last reported valuation was $106 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.

ThinkCyte investors

27 investors are on record for ThinkCyte, including Google for Startups, Global Brain, SMBC Venture Capital and J-Startup. By type, the record holds 5 venture capital firms.

About ThinkCyte

Developer of an image-based cell sorting technology designed to advance single-cell analysis for research, diagnostics, and therapeutics. The company's ghost cytometry technology integrates advanced optics, machine learning, and biotechnology and brings ultra-high throughput, content-rich analysis, and sorting on a single-cell level to disciplines such as drug discovery, cell therapy, and clinical diagnostics, enabling medical researchers to identify cells based on their images and isolate target cells, including rare cells, in real-time.

Sector
Healthcare
HQ
Tokyo, Japan
Founded
2016
Employees
67
Ownership
Privately Held (backing)

Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.